Compare · BSX vs VERO
BSX vs VERO
Side-by-side comparison of Boston Scientific Corporation (BSX) and Venus Concept Inc. (VERO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and VERO operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX carries a market cap of $63.33B.
- BSX has hit the wire 12 times in the past 4 weeks while VERO has been quiet.
- BSX has more recent analyst coverage (25 ratings vs 0 for VERO).
- Company
- Boston Scientific Corporation
- Venus Concept Inc.
- Price
- -
- -
- Market cap
- $63.33B
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 12
- 0
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Venus Concept Inc.
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies worldwide. Its product portfolio includes aesthetic device platforms, including Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Velocity and Venus Epileve, a diode laser device for hair removal, permanent hair reduction, and treatment of ingrown hair; and Venus Fiore that is used for the treatment of vaginal canal, labia skin tightening, and mons pubis. The company also offers Venus Viva, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin; Venus Freeze Plus, a noninvasive device used in dermatologic and general surgical procedures for females for the noninvasive treatment of moderate to severe facial wrinkles and rhytides; Venus Bliss, a device is used for non-invasive lipolysis of the abdomen and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance. In addition, it provides NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system; and ARTAS and ARTAS iX, a robotic systems to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles. The company is headquartered in Toronto, Canada.
Latest BSX
- Chairman, President & CEO Mahoney Michael F received a gift of 252,241 shares (SEC Form 4)
- SVP, Chief HR Officer O'Sullivan Miriam converted options into 3,871 shares and covered exercise/tax liability with 1,872 shares, increasing direct ownership by 11% to 19,565 units (SEC Form 4)
- Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
- SEC Form 10-Q filed by Boston Scientific Corporation
- SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
- Boston Scientific downgraded by TD Cowen with a new price target
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- Boston Scientific downgraded by Oppenheimer
- Boston Scientific downgraded by Analyst with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
Latest VERO
- Venus Concept Obtains Exclusive Distribution Rights for the HIRONIC Doublo 2.0 Device in US and Canada
- Venus Concept Announces Senior Management Changes
- SEC Form D filed by Venus Concept Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Venus Concept Inc.
- Venus Concept Announces Completion of Common Stock Sale and Short-Form Merger
- SEC Form 4 filed by Madryn Asset Management, Lp
- SEC Form 4 filed by Ew Healthcare Partners, L.P.
- SEC Form EFFECT filed by Venus Concept Inc.
- SEC Form EFFECT filed by Venus Concept Inc.
- SEC Form EFFECT filed by Venus Concept Inc.